Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:42:55.524Z.
Calculation as of: 2026-10-06T15:42:55.524Z.
Quote observation: 2026-10-06T15:40:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f972cfcdde9e4531ce3198b66662ffcb9080d57c966754dbe52ec7edaf14096
PE RATIO
N/A
NervGen Pharma Corp. Common stock
Market Cap
$148.36M
PE Ratio
N/A
| NAME | MARKET CAP | PE RATIO |
|---|---|---|
| NervGen Pharma Corp. Common stock (NGEN) | $148.36M | N/A |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.58M | N/A |
| Immuneering Corporation (IMRX)vs › | $145.88M | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $150.96M | N/A |
| Nyxoah S.A. (NYXH)vs › | $143.10M | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $151.99M | N/A |
| Codexis, Inc. (CDXS)vs › | $152.20M | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $154.46M | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $154.75M | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
